This study is looking at how well a hepatitis C (HCV) treatment called glecaprevir-pibrentasvir works for pregnant women who have a history of drug use. Researchers want to see if women take all their medication as prescribed and complete the full 56-day treatment. The study also aims to understand women's experiences with HCV treatment during pregnancy. You may be able to join if you are a pregnant woman, 18 or older, with hepatitis C and a history of past or current drug use. The study is currently unclear on its recruitment status.

Study design

This is an observational study, meaning researchers will watch and collect information without assigning treatments. It plans to enroll 50 participants.

What's involved

You would have four in-person visits over approximately one year. These visits include getting information about HCV treatment, blood tests, and completing questionnaires about your medication.

Compensation

Not stated in the trial record.

Follow-up

You will have a final study visit 4 weeks after completing HCV treatment to check for the virus, and medication adherence and treatment completion rates will be measured at 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.